655248-57-0 Usage
Uses
Used in Organic Synthesis:
4-Amino-2-bromobenzaldehyde is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows for versatile reactions, making it a valuable component in the synthesis of a wide range of organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-amino-2-bromobenzaldehyde is utilized as an intermediate in the synthesis of various drugs. Its presence in the molecular structure of these compounds contributes to their therapeutic properties, making it an essential component in drug development.
Used in Agrochemical Production:
4-Amino-2-bromobenzaldehyde also finds application in the agrochemical sector, where it is used as an intermediate in the synthesis of pesticides and other agricultural chemicals. Its role in these compounds helps to enhance their effectiveness in protecting crops and improving agricultural yields.
Used in Research and Development:
In the field of research and development, 4-amino-2-bromobenzaldehyde is employed for the creation of new compounds with potential applications in various industries. Its unique chemical properties make it a promising candidate for the development of innovative materials and substances with novel properties.
Check Digit Verification of cas no
The CAS Registry Mumber 655248-57-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,5,2,4 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 655248-57:
(8*6)+(7*5)+(6*5)+(5*2)+(4*4)+(3*8)+(2*5)+(1*7)=180
180 % 10 = 0
So 655248-57-0 is a valid CAS Registry Number.
655248-57-0Relevant academic research and scientific papers
4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES
-
Page 51-52, (2010/02/06)
The present invention provides 4-anilido substituted quinazoline compounds which are potent inhibitors of protein tyrosine (PTK) kinase activity, particularly epidermal growth factor receptor (EGFR) kinase activity, and pharmaceutical compositions comprising these compounds. The present invention further provides methods of inhibiting the activity of a protein tyrosine kinase (PTK), for example an EGFR kinase, comprising the step of contacting the PTK with an effective inhibitory amount of any of the quinazoline compounds defined herein. The present invention further provides a method of inhibiting the activity of a protein tyrosine kinase (PTK) in a subject, for example an EGFR kinase, comprising the step of administering to the subject a therapeutically effective amount of any of the quinazoline compounds defined herein. The present invention further provides a method of treating or preventing a protein tyrosine kinase (PTK) related disorder in a subject, for example an EGFR related disorder, comprising the step of administering to the subject a therapeutically effective amount of any of the quinazoline compounds defined herein. The quinazoline compounds are useful in treating a variety of PTK related disorders such as cell proliferative disorders, fibrotic disorders, metabolic disorders and cancer.
